Gene: B3GNTL1
Official Full Name: UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase like 1provided by HGNC
Gene Summary: Enables tRNA-queuosine(34) galactosyltransferase activity. Involved in regulation of translation and tRNA modification. Is active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO23973 | B3GNTL1 Knockout cell line (HeLa) | Human | B3GNTL1 | 1:3~1:6 | Negative | Online Inquiry |
KO23974 | B3GNTL1 Knockout cell line (HCT 116) | Human | B3GNTL1 | 1:2~1:4 | Negative | Online Inquiry |
KO23975 | B3GNTL1 Knockout cell line (HEK293) | Human | B3GNTL1 | 1:3~1:6 | Negative | Online Inquiry |
KO23976 | B3GNTL1 Knockout cell line (A549) | Human | B3GNTL1 | 1:3~1:4 | Negative | Online Inquiry |
B3GNTL1 Gene Knockout Cell Lines are a sophisticated tool designed to facilitate the study of the B3GNTL1 gene's role in glycosylation and its implications for cellular biology. These cell lines are genetically engineered to possess a complete knockout of the B3GNTL1 gene, which encodes for an enzyme involved in the synthesis of specific glycan structures on glycoproteins and glycolipids. By removing the expression of this gene, researchers can investigate its critical contributions to various biological processes such as cell adhesion, signaling, and immune response.
The primary function of B3GNTL1 is to produce specific β1,3-N-acetylglucosaminyltransferases, which are essential for the proper glycosylation of proteins, impacting their stability, localization, and functionality. With the knockout of B3GNTL1, researchers can explore the downstream effects on glycan modifications and their subsequent impacts on protein interactions and cellular pathways. This allows for deeper insights into diseases where glycosylation is disrupted, including cancers and autoimmune disorders.
The scientific importance of B3GNTL1 Gene Knockout Cell Lines extends to both fundamental research and clinical applications. They serve as a valuable model for investigating the biochemical pathways involved in abnormal glycosylation, leading to potential discoveries of therapeutic targets. These cell lines are particularly beneficial for drug screening and development, offering a platform for evaluating the efficacy of compounds that modulate glycosylation pathways.
Compared to other available cell lines, B3GNTL1 Gene Knockout Cell Lines stand out due to their precise gene knockout, which eliminates confounding variables and ensures reproducibility of results. Additionally, the specificity of this knockout allows for a clearer assessment of the precise roles of glycosylation in health and disease, providing researchers with high-quality data.
For researchers and clinicians, the application of B3GNTL1 Gene Knockout Cell Lines can enhance understanding of complex biological systems and streamline the translational pipeline for innovative therapies. This product is not only a crucial asset for advancing glycoscience but also underscores our company’s commitment to providing cutting-edge biotechnological tools backed by extensive scientific expertise and rigorous quality standards.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.